Comprehensive Review of SGLT2i, GLP-1, and Dual/Triple Agonists for Diabesity | Research

The takeaway

Review synthesizes evidence on SGLT2i, GLP-1 RAs, dual and triple incretin agonists as comprehensive pharmacological strategies for the intertwined epidemics of diabetes and obesity.

Full toolkit reviewed
From SGLT2i to triple agonists: comprehensive coverage of current and emerging diabesity pharmacotherapy

What the researchers found

SGLT2i, GLP-1 RAs, and emerging dual/triple agonists offer complementary mechanisms for diabesity management, with clinical evidence supporting progressive pharmacological intensification.

Why it matters

Diabesity affects hundreds of millions globally. Understanding the full pharmacological toolkit enables optimal treatment selection and combination strategies.

How the study worked

Comprehensive narrative review of clinical evidence for SGLT2i, GLP-1 RAs, and multi-receptor agonists in diabesity management.

What this study cannot tell us

Broad review may lack depth on individual drugs. Rapidly evolving field means some information may be superseded quickly.

How to read the evidence

Narrative review synthesizing clinical trial evidence across multiple drug classes.

When this study was published

Published in 2025.

The bigger picture

The diabesity drug landscape is evolving rapidly from single-target to multi-target peptide therapies, with each generation offering greater efficacy.

Questions still open

What is the optimal sequencing of these drug classes?
Should all diabesity patients receive multi-receptor agonists?
How do cost and access affect real-world treatment decisions?

Common questions

What is diabesity?

Diabesity refers to the combination of type 2 diabetes and obesity, which frequently occur together and worsen each other. Modern drugs can now address both conditions simultaneously.

Which drug class is best for diabesity?

GLP-1 drugs and newer dual/triple agonists currently show the strongest evidence for both weight loss and blood sugar control. SGLT2 inhibitors add complementary benefits.

Read the original research

Pharmacological Management of Diabesity: Current and Emerging Therapies.

Current obesity reports, 15(1), 5

View on PubMed ↗Publisher’s paper ↗

Citation

Galasso, Martina; Caporusso, Mariangela; Volatile, Alessandra; Verde, Ludovica; Esposito, Katherine; Giorgino, Francesco; Perrini, Sebastio; Colao, Annamaria; Barrea, Luigi; Muscogiuri, Giovanna. (2026). Pharmacological Management of Diabesity: Current and Emerging Therapies.. Current obesity reports, 15(1), 5. https://doi.org/10.1007/s13679-025-00681-5